Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib in Primary Sjögren's Syndrome
NCT03627065Phase 2Completed
- Sponsor
- Incyte
- Start
- Feb 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of parsaclisib in primary Sjögren's syndrome, sponsored by Incyte. Primary endpoint: Proportion of Participants With a 1 Point or Greater Change on the Salivary Gland Ultrasound Score at Week 12. Started Feb 2019; status: completed.
02
Drugs
parsaclisib
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT03627065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627065.